Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys.
Rare serotype and chimeric recombinant adenovirus (rAd) vectors that evade anti-Ad5 immunity are currently being evaluated as potential vaccine vectors for human immunodeficiency virus type 1 and other pathogens. We have recently reported that a heterologous rAd prime-boost regimen expressing simian immunodeficiency virus (SIV) Gag afforded durable partial immune control of an SIV challenge in rhesus monkeys. However, single-shot immunization may ultimately be preferable for global vaccine delivery. We therefore evaluated the immunogenicity and protective efficacy of a single immunization of chimeric rAd5 hexon hypervariable region 48 (rAd5HVR48) vectors expressing SIV Gag, Pol, Nef, and Env against a homologous SIV challenge in rhesus monkeys. Inclusion of Env resulted in improved control of peak and set point SIV RNA levels following challenge. In contrast, DNA vaccine priming did not further improve the protective efficacy of rAd5HVR48 vectors in this system.
Barouch
Dan H
DH
Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA. dbarouch@bidmc.harvard.edu
Liu
Jinyan
J
Lynch
Diana M
DM
O'Brien
Kara L
KL
La Porte
Annalena
A
Simmons
Nathaniel L
NL
Riggs
Ambryice M
AM
Clark
Sarah
S
Abbink
Peter
P
Montefiori
David C
DC
Landucci
Gary
G
Forthal
Donald N
DN
Self
Steven G
SG
Carville
Angela
A
Mansfield
Keith
K
Goudsmit
Jaap
J
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D005814:Genes, Viral; D015752:Genes, env; D005822:Genetic Vectors / Q000008:administration & dosage*; D007114:Immunization; D008253:Macaca mulatta; D018449:SAIDS Vaccines / Q000008:administration & dosage / Q000494:pharmacology*; D016097:Simian Acquired Immunodeficiency Syndrome / Q000628:therapy*; D015302:Simian Immunodeficiency Virus / Q000276:immunology; D016896:Treatment Outcome
D018449:SAIDS Vaccines